Navigation Links
Minimally Invasive Surgery for Treatment of Colorectal Cancer Yields Optimal Outcomes for Patients
Date:3/20/2013

is key to prevention, and it is worth remembering that colorectal cancer is the only one of the five most common cancers that can actually be prevented by screening – i.e. by removing colorectal polyps before they can turn into cancer. However when patients have to make a decision about treatment, they should be aware that minimally invasive operations are an option in many cases, as easier recovery can often be achieved through minimally invasive surgery (MIS),” said Dr. Scott Melvin, SAGES President and Professor and Chief of Gastrointestinal Surgery and Professor at Ohio State University. “We want patients to know that under the right circumstances, choosing laparoscopic surgery will allow for a more comfortable recovery than an open procedure would and due to briefer recovery times, when necessary, chemotherapy treatment may take place sooner rather than later,” Dr. Melvin said.

Dr. Tonia Young-Fadok, Professor of Surgery at the Mayo Clinic College of Medicine and Chair of the SAGES Humanitarian Task Force added, “Through guidelines such as these SAGES is committed to encouraging patients to be more informed about the options available to them. Patients should feel comfortable asking their surgeon if a minimally invasive procedure is an option, and if not they may wish to seek a second opinion from a surgeon experienced with these operations.”

Guidelines are available at the links above or also at http://www.sages.org/publications/patient_information. SAGES has been at the forefront of best practices in colorectal cancer surgery by researching, developing and disseminating the guidelines and training for standards of practice in surgical procedures. The SAGES 2013 annual conference will be held this spring in Baltimore from April 17th to April 20th and will feature sessions on the latest research and development in the field of minimally invasiv
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study shows long-term efficacy of minimally invasive therapy for patients with Barretts esophagus
2. Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse (POP) Now Available from the Specialists at Women’s Excellence in Bladder Control in Clarkston, MI
3. Fox Valley Orthopedics Surgeon Dr. Craig Popp Says New Minimally Invasive Herniated Disc Surgery Less Painful
4. New technique for minimally invasive robotic kidney cancer surgery
5. Minimally invasive lymph node dissection in breast cancer has advantages over conventional surgery
6. Minimally invasive surgery works well for abdominal aortic aneurysms, Mayo finds
7. Obese appendectomy patients have fewer complications with minimally invasive operations
8. The Joint Facial and Invasive Neck Trauma (J-FAINT) Project, Iraq and Afghanistan 2003-2011
9. Less invasive treatment is associated with improved survival in early stage breast cancer
10. Less invasive treatment may increase survival in early stage breast cancer
11. Long-term survival after less-invasive repair of abdominal aneurysm same as with open procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... BEER-SHEVA, ISRAEL, December 17, 2010 As middle ear ... University of the Negev (BGU) suggest that in many ... instead of using antibiotics immediately. The review, published ... Therapy , does not suggest use of watchful waiting ...
... -- Differences in immune signaling pathways among various species ... primates to certain infectious diseases, researchers say. For ... to AIDS or severe complications from hepatitis B, it ... chimpanzees to the serious effects of these viral infections, ...
... News) Christmas and other winter holidays are supposed to ... the more stressful when they are anything but joyous. ... especially vulnerable to depression, Dr. Angelos Halaris, a psychiatrist with ... release. Shopping and entertaining can be stressful, while reflecting on ...
... research indicates that about half of women age 65 and ... place, the poverty rate for women falls to 12 percent. ... are presented in the latest installment of the Public ... on an Aging Society, the public policy branch of The ...
... THURSDAY, Dec. 16 (HealthDay News) -- U.S. scientists have unraveled ... cancer in children. Gene sequencing reveals that this tumor, ... adult tumors. The discovery that MB has five to ... attempts to understand what triggers the cancer and which treatment ...
... , , , , , ... , AUDIO: People with a known risk ... Click here for more information. , , ... , , , , , ...
Cached Medicine News:Health News:Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children 2Health News:Primate Immune System Differences Identified 2Health News:Surviving the Holiday Blues 2Health News:Brief clarifies Social Security's value for women 2Health News:Gene Research Brings Insight Into Deadly Childhood Brain Tumor 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 4Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 5
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium ... today positive preliminary results from its Phase II ... prednisone (D/P) in men with docetaxel refractory, castrate ... of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in ...
... Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation ... the status of its new drug application ("NDA") for AFRESA(R), ... trials. As previously announced, our internal goal was to ... by the end of February. Based on editorial decisions ...
Cached Medicine Technology:Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 2Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 3Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 4MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: